<DOC>
	<DOC>NCT00372528</DOC>
	<brief_summary>The main purpose of this trial is to allow continued access to pregabalin to Canadian subjects who participated in global pregabalin epilepsy studies 1008-010; 1008-035; 1008-114 and 1008-164 and to continue to study the long term safety of pregabalin administered as adjunctive therapy at dosages from 150 mg/day to 600 mg/day in Canadian subjects with refractory partial seizures.</brief_summary>
	<brief_title>An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Must have completed Pfizer openlabel studies 1008010; 1008035; 1008114 or 1008164 and wishes to continue receiving openlabel pregabalin Must have responded favorably to pregabalin in Pfizer openlabel study 1008010, 1008035, 1008114 or 1008164 and in the clinical opinion of the investigator continued treatment with pregabalin is in the the patient's best medical interest Is pregnant or is considering becoming pregnant during the course of the study Experienced a serious adverse event during openlabel Pfizer study 1008010, 1008035, 1008114 or 1008164</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>